echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > BMC Gastroenterology: trough level of infliximab is associated with histological remission of inflammatory bowel disease

    BMC Gastroenterology: trough level of infliximab is associated with histological remission of inflammatory bowel disease

    • Last Update: 2021-03-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Even though the types of monoclonal antibodies for the treatment of inflammatory bowel disease continue to develop, infliximab is still the main treatment drug for inflammatory bowel disease (IBD).


    Even though the types of monoclonal antibodies for the treatment of inflammatory bowel disease continue to develop, infliximab is still the main treatment drug for inflammatory bowel disease (IBD).


     

     

    Researchers conducted a prospective cohort study of 104 patients with IBD at a tertiary medical center in London, Canada.


     

     

    The results of the study confirmed that compared with patients with active disease (6.


     

     

    This study confirmed that trough infliximab concentration greater than 8μg/ml in the maintenance phase is highly correlated with histological remission and sustained histological remission.


    This study confirmed that trough infliximab concentration greater than 8μg/ml in the maintenance phase is highly correlated with histological remission and sustained histological remission.


     

    Original source:

    Aze Wilson.


    biomedcentral.
    com/articles/10.
    1186/s12876-021-01650-7" target="_blank" rel="noopener">High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.